Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival-Reference-Cited by-同舟云学术

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Published:2021-08 Issue:8 Volume:32 Page:1015-1024
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Slamon D.J.,Neven P.,Chia S.,Jerusalem G.,De Laurentiis M.,Im S.,Petrakova K.,Valeria Bianchi G.,Martín M.,Nusch A.,Sonke G.S.,De la Cruz-Merino L.,Beck J.T.,Ji Y.,Wang C.,Deore U.,Chakravartty A.,Zarate J.P.,Taran T.,Fasching P.A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference15 articles.

1. Targeting CDK4/6 in patients with cancer;Hamilton;Cancer Treat Rev,2016

2. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts;Fry;Mol Cancer Ther,2004

3. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro;Finn;Breast Cancer Res,2009

4. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3;Slamon;J Clin Oncol,2018

5. Ribociclib as first-line therapy for HR-positive, advanced breast cancer;Hortobagyi;N Engl J Med,2016

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation;Cancer Treatment Reviews;2024-11

2. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

3. Niveles de creatinina elevados y cistatina normales en un paciente que recibe ribociclib;Nefrología;2024-09

4. Die CAPTOR-BC-Studie;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2024-09

5. CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis;BMC Cancer;2024-08-21